期刊文献+

复方阿仑膦酸钠缓释片的制备及体外释放度考察 被引量:6

Preparation and Release of Compound Alendronate Sodium Sustained-release Tablet in Vitro
原文传递
导出
摘要 目的:制备复方阿仑膦酸钠缓释片并考察其体外释放度。方法:以羟丙基甲基纤维素(HPMC)、乙基纤维素(EC)、无水乳糖处方用量为因素,体外释放度为指标,用正交试验优化处方,以湿法制粒压片制备制剂,并考察其体外释放度。结果:筛选最优处方为HPMC 80mg、EC 20mg、无水乳糖20mg。所制制剂可持续12h释药,释放行为符合Higuchi方程。结论:所制缓释片的处方合理,具有良好的缓释效果。 OBJECTIVE: To prepare compound alendronate sodium sustained - release tablet and to investigate its drug release profile in vitro. METHODS: Hydroxy propyl methylcellulose (HPMC), ethylcellulose (EC), and lactis anhydrous were used to prepare sustained - release tablets by wet granule compression technique with release rate in vitro as index. Orthogonal experiment was conducted to optimize the formula. The release rate of the tablets in vitro was investigated. RESULTS: The optimized formula was as follows: HPMC 80 mg, EC 20 mg, and lactis anhydrous 20 mg. 12 h drug release of the preparation was achieved, and the drug release behavior in vitro fitted Higuchi equation. CONCLUSION: The sustained-release tablet is reasonable in formula and satisfactory in slow release efficacy.
出处 《中国药房》 CAS CSCD 北大核心 2008年第34期2690-2692,共3页 China Pharmacy
关键词 阿仑膦酸钠 缓释片 正交设计 体外释放度 Alendronate sodium Sustained - release tablet Orthogonal design Release rate in vitro
  • 相关文献

参考文献7

二级参考文献14

  • 1易涛,易以木.洛伐他汀缓释片的质量控制研究[J].中国药房,2004,15(11):670-671. 被引量:3
  • 2钱春梅,吴娇芬,陈芳晓,岳婕.硝苯地平固体分散体胶囊剂的制备[J].中国医院药学杂志,2005,25(6):521-523. 被引量:13
  • 3张森.FDA批准改良的Fosamax[J].国外药讯,2005(7):31-31. 被引量:3
  • 4Kuljanin J,Jankovic I,Nedeljkovic J,et al.Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions[J].J Pharm Biomed Anal,2002,28(6):1215
  • 5Yun MH,Kwon KI.High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence:application to a pharmacokinetic study in humans[J].J Pharm Biomed Anal,2006,40(1):168
  • 6Tsai E.W,Singh M.M,Lu H.H,et al.Application of capillary electrophoresis to phammceutical analysis-determination of alendronate in dosage forms[J].J Chromatogr,1992,626:245.
  • 7Reed D.G,Martin G.P,Konieczny J.M,et al.The determination of alendronate sodium in tablets by inductively coupled plasma(ICP)[J].J Pharm Biomed Anal,1995,13(8):1055
  • 8国家食品药品监督管理局国家药品标准[S].WS1-(X-312)-2004.
  • 9国家药典委员会编.中华人民共和国卫生部药品标准-化学药品及制剂[S].第1册.北京:化学工业出版社,2004:56.
  • 10曾环想,潘卫三,陈济民,庄殿友,吴涛,王涛.法莫替丁缓释片的制备工艺及其体外释放特性的研究[J].中国药学杂志,1997,32(4):213-216. 被引量:22

共引文献34

同被引文献39

  • 1金朝辉,蒋学华,徐伟娟,陈卓,袁子雁.黄藤素缓释片释放度的测定及其释药特性[J].华西药学杂志,2005,20(2):113-115. 被引量:7
  • 2王珣,孙佩男,栾琳,孟晋,李颖,潘卫三.别嘌醇缓释片的制备及释药机理的初步探讨[J].沈阳药科大学学报,2007,24(3):138-141. 被引量:9
  • 3Drug Specification Promulgated by Theministry of Public Health, China. Part 2, Vol 7(卫生部药品标准二部第七册)【S].1996:39-40.
  • 4ZHANGMY LILD.Advance in the houttuyniae and its preparations .中药药理与临床,2010,26(2):79-85.
  • 5XIEY NIEZY.Preparation and quality control of tramadol hydrochloride sustained release table .中国现代应用药学,2006,23(8):781-782.
  • 6王玉鹏,赵丽华,胡容峰.缓释骨架材料在药物制剂中的应用[J].中国药房,2007,18(25):1987-1988. 被引量:8
  • 7McConville B J, Arvanitis LA, Thyrum PT, et al. Pharma- cokinetics, tolerability, and clinical effectiveness of que- tiapine fumarate: an open-label trial in psychotic disorders[J]. J Clin Psychiatry, 2000,61 (4) : 252.
  • 8Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: precli- nical studies, pharmacokinetics, drug interactions, and dosing[J]. J Clin Psychiatry, 2002,63 (Suppl 13) : 5.
  • 9丹尼尔-布朗唐娜·卡斯特,布赖恩·克拉克桑德拉·霍普金斯,詹妮弗·卢埃林莉萨·马丁,等.包含喹硫平的延释组合物及其制备方法[P]_中国:101754752A,2010一06-23.
  • 10梁文权.生物药剂学与药物动力学[M].第4版.北京:人民卫生出版社,2008:38.

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部